Bioeq AG is a Swiss biopharmaceutical company. Bioeq licenses, develops and commercializes biological successor products of successful biopharmaceuticals, called biosimilars.
FYB201 is currently the most advanced biosimilar program of Bioeq. The clinical studies and registration are conducted by bioeq GmbH based in Holzkirchen, Germany, on behalf of Bioeq AG.
Phone: +41 44 533 41 00